Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
about
Therapy for Parkinson's disease: what is in the pipeline?Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's DiseaseLevodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsThe effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experienceIntegrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Management of motor and non-motor symptoms in Parkinson's disease.Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.Carbidopa levodopa enteral suspension.Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.Algorithms for the treatment of motor problems in Parkinson's disease.Progress in European neurology 2012-2013.Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
P2860
Q26991826-6E7912EB-7BD1-4940-8F8E-E93841A281C4Q27325443-2E72F01A-6B06-48F5-BF90-29B0CC02C888Q36361513-57B53C39-B342-43E1-BC34-6948ED936D6EQ36724032-CE4047B8-0389-409C-B02E-ECDFD2CF8524Q37340428-87D7F864-935B-432E-9A3B-EAF967A2B4EFQ37698585-A79A4B41-BC8B-476E-BBF4-1C349EF707EDQ38091653-2C0EB70C-8AAE-408B-9C7C-71E6949C49B5Q38194569-54F0B838-C0BC-4697-BCEE-B4A3956B015EQ38643494-9111569F-7F43-4CB7-80AA-76D4B785EC0BQ38823793-E32FFA0F-E813-4F88-90F0-3D274834C494Q38992788-2E28BBAE-DF90-421E-8424-BBC3E2639F47Q46040914-EC0A6729-3FB6-460E-9555-D8F62D469507Q47652358-8BEFC503-BB3C-42C3-BB0E-07F8BBB85BBAQ47997995-10D8529F-0836-403E-843D-6CB63ACBFDA9Q48064134-0A5DF923-ED2A-45B7-A53C-05F98B8C391CQ48128791-04ADD23A-F5CC-46B7-9E93-9AC11F6E7CCDQ53143036-C57C57F5-02FC-405C-8FB3-843B0A0EBA49Q53661046-AA38CC45-8356-4893-A169-64C5184F3E46Q54328579-CAB05ADF-54F8-449B-90A2-EE44C2A3BD00Q54478924-95C677B6-FCAB-4024-85BF-A1EB9687598A
P2860
Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@en
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@nl
type
label
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@en
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@nl
prefLabel
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@en
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@nl
P2093
P1476
Levodopa/carbidopa intestinal ...... advanced Parkinson's disease.
@en
P2093
P304
P356
10.1111/J.1468-1331.2012.03679.X
P577
2012-02-23T00:00:00Z